| |
|
| Breast Cancer Clinical Trials |
 |
| Other breast cancer clinical trials |
|
| |
|
PHASE III RANDOMIZED STUDY OF AEROSOLIZED RIBAVIRIN
VERSUS STANDARD SUPPORTIVE THERAPY IN PATIENTS WITH RESPIRATORY
SYNCYTIAL VIRUS FOLLOWING STEM CELL TRANSPLANTATION Open
Protocol
PROTOCOL IDS:
FHCRC-1290.00, NCI-G01-1939
STUDY CONTACT:
Michael Boeckh, Chair Ph: 206-667-4898
Fred Hutchinson Cancer Research Center
Seattle, Washington
PHASE III RANDOMIZED STUDY OF AMPHOTERICIN B-LIPOSOMAL
FORMULATION INITIATED 72-84 HOURS VS 144-156 HOURS AFTER ONSET OF
A FEBRILE EPISODE IN CANCER PATIENTS WITH GRANULOCYTOPENIA AND PERSISTENT
UNEXPLAINED FEVER REFRACTORY TO ANTIBACTERIALS Open
Protocol
PROTOCOL IDS: EORTC-19951
STUDY CONTACT:
P. Ljungman, Chair Ph: 468-585-8000
EORTC Invasive Fungal Infections Group
PHASE III RANDOMIZED STUDY OF DOXORUBICIN IN COMBINATION
WITH EITHER DOCETAXEL OR CYCLOPHOSPHAMIDE IN WOMEN WITH POTENTIALLY
OPERABLE, LOCALLY ADVANCED OR INFLAMMATORY BREAST CANCER Open
Protocol
PROTOCOL IDS: SCTN-BR9809; EU-98053
STUDY CONTACT:
T.R.J. Evans, Ph: 0141-330-4171
C.R.C. Beatson Laboratories
Glasgow, Scotland, United Kingdom
PHASE III RANDOMIZED STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE,
THIOTEPA, AND CARBOPL ATIN AND AUTOLOGOUS BONE MARROW OR PERIPHERAL
BLOOD STEM CELL
TRANSPLANTATION IN CONJUNCTION WITH C YCLOSPORINE AND INTERFERON
GAMMA VERSUS INTERLEUKIN-2 AS IMMUNOMODULATION IN WOMEN WITH HIGH-RISK
STAGE II OR III BREAST CANCER Open
Protocol
PROTOCOL IDS: CPMC-IRB-7608; NCI-G00-1890;
CPMC-CAMP-014
STUDY CONTACT:
Charles S. Hesdorffer, Ph: 212-305-4907
Herbert Irving Comprehensive Cancer Center
New York, New York, U.S.A.
PHASE III RANDOMIZED STUDY OF PROPHYLACTIC LEVOFLOXACIN
AFTER CHEMOTHERAPY IN PATIENTS WITH SOLID TUMORS OR LYMPHOMA Open
Protocol
PROTOCOL IDS: CRC-TU-SIGNIFICANT,
EU-99054
STUDY CONTACT:
Steven M. Neil, Ph: 0121-414-2803
University of Birmingham
Birmingham, England, United Kingdom
PHASE III RANDOMIZED STUDY OF SHARK CARTILAGE (BENEFIN)
IN PATIENTS WITH ADVANCED COLORECTAL OR BREAST CANCER Open
Protocol
PROTOCOL IDS: NCCTG-971151, NCCAM
STUDY CONTACT:
Charles L. Loprinzi, Chair Ph: 507-284-8964
North Central Cancer Treatment Group
PHASE III RANDOMIZED STUDY OF VALGANCICLOVIR TO PREVENT
LATE CYTOMEGALOVIRUS INFECTION IN PATIENTS WHO HAVE UNDERGONE ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION Open
Protocol
PROTOCOL IDS: FHCRC-1577.00, NCI-H01-0072
STUDY CONTACT:
Michael Boeckh, Chair Ph: 206-667-4898
Fred Hutchinson Cancer Research Center
Seattle, Washington
PHASE III STUDY OF MAINTENANCE IMMUNOTHERAPY WITH
CORYNEBACTERIUM GRANULOSUM P40 IN PATIENTS WITH COLON CANCER, BREAST
CANCER, OR MELANOMA WITH MINIMAL RESIDUAL DISEASE AFTER SURGICAL
RESECTION Open
Protocol
PROTOCOL IDS: ARG-CO/BR-1
STUDY CONTACT:
Hugo Omar De Carli, Chair Ph: 021-84-3119
Centro Oncologico de Excelencia
Gonnet, Buenos Aires, Argentina
PHASE II/III RANDOMIZED STUDY OF MONOCLONAL ANTIBODY
ABX-CBL VERSUS ANTI-THYMOCYTE GLOBULIN IN PATIENTS WITH STEROID
RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE Open
Protocol
PROTOCOL IDS: UCLA-9911052, NCI-G01-1916,
ABX-CB-9906
STUDY CONTACT:
Mary Carol Territo, Chair Ph: 310-206-5755
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
SCREENING AND DIAGNOSTIC STUDY OF DIGITAL MAMMOGR
A-PHY VERSUS SCREEN-FILM MAMMOGRAPHY IN THE DETECTION OF BREAST
CANCER IN WOMEN Open
Protocol
PROTOCOL IDS: ACRIN-6652
STUDY CONTACT:
Etta Pisano, Chair, Ph: 919-966-6957
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, USA
SCREENING AND DIAGNOSTIC STUDY OF MAGNETIC RESONANCE
IMAGING IN WOMEN WITH SUSPECTED BREAST CANCER Open
Protocol
PROTOCOL IDS: UPCC-ACR-6884
STUDY CONTACT:
Mitchell Schnall, Ph: 215-662-7238
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
PHASE II PILOT STUDY COMPARING DOXORUBICIN (ADRIAMYCIN)
AND PACLITAXEL (TAXOL) INDUCED LOCALLY ADVANCED BREAST CANCER Open
Protocol
PROTOCOL IDS: GUMC-97018; NCI-V97-1276
STUDY CONTACT:
Daniel F. Hayes, Ph: 734-615-6725
Vincent T. Lombardi Cancer Research Center
Georgetown University
Washington, District of Columbia
PHASE II PILOT STUDY OF ADJUVANT PACLITAXEL, CYCLOPHOSPHAMIDE,
FILGRASTIM (G-CSF), AND DOXORUBICIN FOLLOWED BY RADIOTHERAPY IN
PATIENTS WITH STAGE II OR IIIA BREAST CANCER
Open Protocol
PROTOCOL IDS: CWRU-1100; NCI-G00-1877;
CWRU-050023
STUDY CONTACT:
Brenda W. Cooper, Ph: 216-844-3213
Ireland Cancer Center
Cleveland, Ohio
PHASE II PILOT STUDY OF CYCLOPHOSPHAMIDE AND ACTIVE
INTRALYMPHATIC IMMUNOTHERAPY WITH A VACCINE CONTAINING INTERFERON
ALFA OR INTERFERON GAMMA TREATED TUMOR CELLS FOLLOWED BY SARGRAMOSTIM
(GM-CSF) IN PATIENTS WITH ADVANCED CANCERS Open
Protocol
PROTOCOL IDS: SVMC-ONC-222, NCI-V91-0075
STUDY CONTACT:
Charles L. Wiseman, Chair Ph: 213-484-7575
St. Vincent Medical Center - Los Angeles
Los Angeles, California
PHASE II PILOT STUDY OF P53 VACCINE IN PATIENTS WITH
STAGE IV, RECURRENT, OR PROGRESSIVE ADENOCARCINOMA OF THE BREAST
Open
Protocol
PROTOCOL IDS: NCI-99-C-0138, NCI-T99-0075,
NCI-NMOB-9902
STUDY CONTACT:
Samir N. Khleif, Ph: 301-435-5392
Medicine Branch
Bethesda, Maryland, U.S.A
PHASE II PILOT STUDY OF TUMOR-SPECIFIC P53 OR RAS
VACCINES WITH OR WITHOUT CELLULAR IMMUNOTHERAPY WITH PEPTIDE-ACTIVATED
LYMPHOCYTES PLUS INTERLEUKIN-2 IN PATIENTS WITH TUMORS EXPRESSING
MUTANT P53 OR RAS Open
Protocol
PROTOCOL IDS: NCI-95-C-0105A; NCI-T94-0096N
STUDY CONTACT:
Samir N. Khleif, Ph: 301-435-5392
Medicine Branch
Bethesda, Maryland
PHASE II RANDOMIZED STUDY OF METHOTREXATE WITH OR
WITHOUT ANTINEOPLASTON A10 CAPSULES IN WOMEN WITH ADVANCED BREAST
CANCER Open
Protocol
PROTOCOL IDS: BRI-BR-10; B-New-65
STUDY CONTACT:
Stanislaw R. Burzynski, Ph: 713-335-5697
Burzynski Research Institute
Houston, Texas
PHASE II RANDOMIZED STUDY OF SOY ISOFLAVONE IN PATIENTS
WITH BREAST CANCER Open
Protocol
PROTOCOL IDS: UCLA-000509301, NCI-G01-1994
STUDY CONTACT:
Mai Nguyen, Chair Ph: 310-206-2215
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
PHASE II STUDY OF ALLOGENEIC MIXED CHIMERISM PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION UTILIZING IN VIVO AND IN VITRO MONOCLONAL
ANTIBODY CD52 (CAMPATH-1H) IN PATIENTS WITH HIGH RISK HEMATOLOGIC
MALIGNANCIES OR DISEASES Open
Protocol
PROTOCOL IDS: DUMC-1340-99-7; NCI-G99-1617
STUDY CONTACT:
David A. Rizzieri, Ph: 919-668-1040
Duke Comprehensive Cancer Center
Durham, North Carolina
PHASE II STUDY OF BRYOSTATIN 1 FOR THE TREATMENT
OF STAGE IV BREAST CANCER Open
Protocol
PROTOCOL IDS: UCHSC-97751; NCI-T97-0063
STUDY CONTACT:
Andrew S. Kraft, Ph: 303-315-8802
University of Colorado Cancer Center
Denver, Colorado
PHASE II STUDY OF CONCURRENT BEVACIZUMAB AND VINOREL-BINE
IN PATIENTS WITH STAGE IV BREAST CANCER Open
Protocol
PROTOCOL IDS: DFCI-01013, NCI-2716
STUDY CONTACT:
Harold J. Burstein, Chair Ph: 617-632-3800
Dana-Farber Cancer Institute
Boston, Massachusetts
PHASE II STUDY OF CP-358,774 IN WOMEN WITH PROGRESSIVE
OR RECURRENT, LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Open Protocol
PROTOCOL IDS: MSKCC-01068; NCI-G01-2012;
GENENTECH-OSI2288g
STUDY CONTACT:
Maura Dickler, Chair Ph: 212-639-5456
Memorial Sloan-Kettering Cancer Center
New York, New York
PHASE II STUDY OF CYTOKINE-BASED IMMUNOTHERAPY FOLLOWING
HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION
IN PATIENTS WITH HIGH RISK CANCER Open
Protocol
PROTOCOL IDS: MRMC-CTCA-9801, NCI-V98-1449
STUDY CONTACT:
Anastasio Raptis, Chair, Ph: 847-872-6425
Midwestern Regional Medical Center
Zion, Illinois
PHASE II STUDY OF DOCETAXEL IN CAUCASIAN AND AFRICAN
AMERICAN PATIENTS WITH SOLID TUMORS Open
Protocol
PROTOCOL IDS: CLB-9871
STUDY CONTACT:
Lionel D. Lewis, Chair Ph: 603-650-8685
Cancer and Leukemia Group B
PHASE II STUDY OF DOCETAXEL, VINORELBINE, AND FILGRASTIM
(G-CSF) IN WOMEN WITH HER-2 NEGATIVE STAGE IV BREAST CANCER Open
Protocol
PROTOCOL ID: SWOG-S0102
STUDY CONTACT:
Julie R. Gralow, Chair Ph: 206-288-1233
Southwest Oncology Group
PHASE II STUDY OF DOSE INTENSIVE CHEMOTHERAPY AND
STEM CELL RESCUE IN PATIENTS WITH INFLAMMATORY STAGE IIIB BREAST
CANCER Open
Protocol
PROTOCOL IDS: CHNMC-96139; NCI-G97-1288
STUDY CONTACT:
George Somlo, Ph: 626-359-8111
Beckman Research Institute, City of Hope
Los Angeles, California
PHASE II STUDY OF ORAL ANTINEOPLASTONS A10 AND AS2-1
IN PATIENTS WITH ADVANCED BREAST CANCER Open
Protocol
PROTOCOL ID: BRI-BR-14
STUDY CONTACT:
Stanislaw R. Burzynski, Ph: 713-335-5697
Burzynski Research Institute
Houston, Texas
PHASE II STUDY OF REBECCAMYCIN ANALOGUE IN PATIENTS
WITH STAGE IIIB OR IV BREAST CANCER Open
Protocol
PROTOCOL IDS: DFCI-99283; NCI-197;
CWRU-DFCI-1199
STUDY CONTACT:
Harold J. Burstein, Ph: 617-632-3800
Dana-Farber Cancer Insitute
Boston, Massachusetts
PHASE II STUDY OF WHOLE BODY HYPERTHERMIA COMBINED
WITH DOXORUBICIN HCL LIPOSOME AND FLUOROURACIL IN PATIENTS WITH
ADVANCED BREAST, OVARIAN, ENDOMETRIAL, OR CERVICAL CANCER Open
Protocol
PROTOCOL IDS: UTHSC-MS-96205, NCI-V97-1356
STUDY CONTACT:
Joan M.C. Bull, Ph: 713-500-6821
University of Texas Health Science Center - Houston
Houston, Texas, U.S.A.
STUDY OF STEM CELL AUGMENTED, ELUTRIATED GRAFTS FOR
PREVENTION OF GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING ALLOGENEIC
BONE MARROW TRANSPLANTATION Open
Protocol
PROTOCOL IDS: JHOC-97021903; NCI-V98-1460;
JHOC-J9711
STUDY CONTACT:
Richard J. Jones, Chair Ph: 410-955-2813
Johns Hopkins Oncology Center
Baltimore, Maryland
PHASE I/II RANDOMIZED STUDY OF EX VIVO EXPANDED MEGAKARYOCYTES
IN PATIENTS WITH BREAST CANCER OR HEMATOLOGIC MALIGNANCIES Open
Protocol
PROTOCOL IDS: NU-97B2; NCI-V00-1611
STUDY CONTACT:
Jane N. Winter, Ph: 312-695-6180
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois
PHASE I/II STUDY OF BMS-247550 IN PATIENTS WITH ADVANCED
SOLID TUMORS OR ADVANCED OR RECURRENT OVARIAN EPITHELIAL OR BREAST
CANCER Open
Protocol
PROTOCOL IDS: AECM-9911378, NCI-98
STUDY CONTACT:
Sridhar Mani, Ph: 718-904-2488
Albert Einstein Comprehensive Cancer Center
Bronx, New York, U.S.A.
PHASE I/II STUDY OF HIGH DOSE MELPHALAN WITH AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL SUPPORT AND AMIFOSTINE CYTOPROTECTION
IN CANCER PATIENTS Open
Protocol
PROTOCOL IDS: UKMC-97BMT72, NCI-V98-1455,
ALZA-UKMC-97BMT72
STUDY CONTACT:
Donna E. Reece, Chair Ph: 416-946-2253
University of Toronto, Princess Margaret Hospital
Toronto, Canada
PHASE I/II STUDY OF HIGH-DOSE CHEMOTHERAPY FOLLOWED
BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AND IMMUNOTHERAPY
WITH ACTIVATED T CELLS, INTERLEUKIN-2, AND SARGRAMOSTIM (GM-CSF)
IN PATIENTS WITH STAGE IIIB OR IV BREAST CANCER OR OTHER SOLID TUMORS
Open Protocol
PROTOCOL IDS: RWMC-0034246
STUDY CONTACT:
Lawrence G. Lum, Chair Ph: 401-456-2672
Roger Williams Medical Center/BUSM
Providence, Rhode Island
PHASE I/II STUDY OF IMMUNOTHERAPY WITH ACTIVATED
T CELLS, INTERLEUKIN-2, AND SARGRAMOSTIM (GM-CSF) IN WOMEN WITH
STAGE IV BREAST CANCER Open
Protocol
PROTOCOL IDS: RWMC-0135146
STUDY CONTACT:
Lawrence G. Lum, Ph: 401-456-2672
Roger Williams Medical Center/BUSM
Providence, Rhode Island, U.S.A.
PHASE I/II STUDY OF SAMARIUM 153 AND AUTOLOGOUS BONE
MARROW TRANSPLANTATION FOR STAGE IV BREAST CANCER Open
Protocol
PROTOCOL IDS: LSU-97447; NCI-V97-1341
STUDY CONTACT:
Benjamin Barry Weinberger, Ph: 318-675-5972
Louisiana State University School of Medicine
Shreveport, Louisiana
PHASE I/II STUDY OF SEQUENTIAL PACLITAXEL, DOXORUBICIN,
AND CYCLOPHOSPHAMIDE FOLLOWED BY IMMUNOTHERAPY WITH ACTIVATED T
CELLS, INTERLEUKIN-2, AND SARGRAMOSTIM (GM-CSF) IN WOMEN WITH HIGH-RISK
STAGE II OR III BREAST CANCER Open
Protocol
PROTOCOL IDS: RWMC-0033846
STUDY CONTACT:
Lawrence G. Lum, Chair Ph: 401-456-2672
Roger Williams Medical Center/BUSM
Providence, Rhode Island
PHASE I/II PILOT STUDY OF STEM CELL MOBILIZATION
WITH PACLITAXEL AND CYCLOPHOSPHAMIDE FOLLOWED BY HIGH DOSE MELPHALAN
AND ETOPOSIDE WITH AUTOLOGOUS PERIPHERAL BLOOD STEM CELL RESCUE
IN PATIENTS WITH METASTATIC OR HIGH RISK BREAST CANCER Open
Protocol
PROTOCOL IDS: NCI-96-C-0104G; NCI-T95-0078N
STUDY CONTACT:
Ronald E. Gress, Ph: 301-435-4654
Medicine Branch
Bethesda, Maryland
PHASE I/II STUDY OF ACTIVE IMMUNOTHERAPY WITH CARCINOEMBRYONIC
ANTIGEN (CEA) RNA PULSED AUTOLOGOUS DENDRITIC CELLS IN PATIENTS
WITH METASTATIC BREAST CANCER WHO ACHIEVE A COMPLETE RESPONSE AFTER
HIGH DOSE CHEMOTHERAPY AND STEM CELL SUPPORT Open
Protocol
PROTOCOL IDS: DUMC-97148; NCI-G98-1455
STUDY CONTACT:
Herbert Kim Lyerly, Ph: 919-681-8350
Duke Comprehensive Cancer Center
Durham, North Carolina
PHASE I/II STUDY OF CAPECITABINE AND VINORELBINE
IN ELDERLY WOMEN WITH METASTATIC BREAST CANCER WITH OR WITHOUT BONE
INVOLVEMENT Open
Protocol
PROTOCOL IDS: SWS-SAKK-25/99; EU-99007
STUDY CONTACT:
D. Hess, Ph: 071-494-11-11
Kantonsspital - Saint Gallen
Saint Gallen, Switzerland
PHASE I/II STUDY OF INTRAHEPATIC DOXORUBICIN ADSORBED
TO MAGNETIC TARGETED CARRIERS IN PATIENTS WITH METASTATIC CANCER
TO THE LIVER OR ADVANCED HEPATOCELLULAR CARCINOMA Open
Protocol
PROTOCOL IDS: FERX-MTC-DOX-003;
UCSF-00454; UCSF-H5535-17999-01D
STUDY CONTACT:
Joy Koda, Chair Ph: 858-677-7788
FeRx Incorporated
PHASE I STUDY OF RECOMBINANT FOWLPOX-CEA-TRICOM VACCINE
WITH OR WITHOUT SARGRAMOSTIM (GM-CSF) OR FOWLPOX-GM-CSF IN PATIENTS
WITH ADVANCED OR METASTATIC CEA-EXPRESSING ADENOCARCINOMAS Open
Protocol
PROTOCOL IDS: FCCC-01016, NCI-1133
STUDY CONTACT:
Margaret von Mehren, Chair Ph: 215-728-2570
Fox Chase Cancer Center
PHASE I STUDY OF MVF-HER-2(628-647)-CRL 1005 VACCINE
IN PATIENTS WITH METASTATIC OR RECURRENT CANCER Open
Protocol
PROTOCOL IDS: UAB-0020, NCI-G01-1955
STUDY CONTACT:
Pierre Lorenzo Triozzi, Chair Ph: 205-975-2833
University of Alabama Comprehensive Cancer Center
PHASE I STUDY OF RECOMBINANT VACCINIA DF3/MUC1 VACCINE
IN PATIENTS WITH METASTATIC BREAST CANCER Open
Protocol
PROTOCOL IDS: DFCI-97050; NCI-T98-0057
STUDY CONTACT:
Donald W. Kufe, Ph: 617-632-3141
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Boston, Massachusetts
PHASE I STUDY OF YTTRIUM Y 90 LABELED, HUMANIZED
MONO-CLONAL ANTIBODY BRE-3 AND INDIUM IN 111 LABELED, HUMAN-IZED
MONOCLONAL ANTIBODY BRE-3 FOLLOWED BY AUTOLO-GOUS BONE MARROW OR
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH METASTATIC
BREAST CAN-CER Open
Protocol
PROTOCOL IDS: CRICC-BB-IND-7186;
NCI-V00-1637; UCHSC-97467
STUDY CONTACT:
Jerry A. Peterson, Ph: 415-431-3330
Cancer Research Institute of Contra Costa
San Francisco, California
PHASE I STUDY OF YTTRIUM Y 90 MONOCLONAL ANTIBODY
B3 FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
IN PATIENTS WITH RELAPSED OR METASTATIC BREAST CANCER Open
Protocol
PROTOCOL IDS: NCI-00-C-0206; NCI-213
STUDY CONTACT:
Michael Bishop, Chair, Ph: 301-435-2764
Division of Clinical Sciences
Bethesda, Maryland
PHASE I STUDY OF YTTRIUM Y 90 MONOCLONAL ANTIBODY
M170, CYCLOSPORINE AND PACLITAXEL IN PATIENTS WITH RECURRENT OR
REFRACTORY METASTATIC BREAST CANCER Open
Protocol
PROTOCOL IDS: UCD-992080, NCI-V00-1640
STUDY CONTACT:
Carol M. Richman, Chair Ph: 916-734-3771
University of California Davis Cancer Center
Sacramento, California
PHASE I STUDY OF NEOADJUVANT CAPECITABINE, CYCLOPHOSPHAMIDE,
AND EPIRUBICIN IN WOMEN WITH LOCALLY ADVANCED OR INFLAMMATORY OR
LARGE OPERABLE BREAST CANCER Open
Protocol
PROTOCOL IDS: IDBBC-10991-CEX
STUDY CONTACT:
Herve Bonnefoi, Ph: 011-44-22-382-33-11
Hopital Cantonal Universitaire de Geneva
Geneva, Switzerland
PHASE I STUDY OF CRYOSURGERY IN WOMEN WITH HIGHLY
SUSPICIOUS BREAST LESIONS Open
Protocol
PROTOCOL IDS: UCLA-9908076; NCI-G01-1964
STUDY CONTACT:
Helena R. Chang, Chair, Ph: 310-794-5624
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
PHASE I STUDY OF DOCETAXEL, GEMCITABINE, AND FILGRASTIM
(G-CSF) IN PATIENTS WITH ADVANCED SOLID TUMORS Open
Protocol
PROTOCOL IDS: DMS-9933; NCI-G01-1933
STUDY CONTACT:
Konstantin H. Dragnev, Chai, Ph: 603-650-6345
Norris Cotton Cancer Center
Lebanon, New Hampshire
PHASE I STUDY OF FLAVOPIRIDOL AND CISPLATIN OR CARBOPLATIN
IN PATIENTS WITH ADVANCED SOLID TUMORS Open
Protocol
PROTOCOL IDS: MAYO-950101, NCI-T97-0032
STUDY CONTACT:
Keith C. Bible, Chair:
507-284-2511
Mayo Clinic Cancer Center
PHASE I STUDY OF INTERLEUKIN-12 AND INTERLEUKIN-2
IN PATIENTS WITH REFRACTORY OR ADVANCED SOLID TUMORS Open
Protocol
PROTOCOL IDS: NCI-00-C-0121; NCI-41
STUDY CONTACT:
Jon M. Wigginton, Chair, Ph: 301-846-5468
Center for Cancer Research
Bethesda, Maryland
PHASE I STUDY OF INTRAPERITONEAL AMINOCAMPTOTHECIN
COLLOIDAL DISPERSION IN PATIENTS WITH CANCER PREDOMINANTLY CONFINED
TO THE PERITONEAL CAVITY Open
Protocol
PROTOCOL IDS: NYU-9753; NCI-T97-0123
STUDY CONTACT:
Franco M. Muggia, Ph: 212-263-6485
NYU School of Medicine’s Kaplan Comprehensive Cancer Center
New York, New York
PHASE I STUDY OF INTR ATHECAL MAFOSFAMIDE IN PATIENTS
WITH REFRACTORY MENINGEAL MALIGNANCIES Open
Protocol
PROTOCOL IDS: NCI-90-C-95H, NCI-T89-0174N
STUDY CONTACT:
Frank Milton Balis, Chair Ph: 301-496-0085
Center for Cancer Research
Bethesda, Maryland
PHASE I STUDY OF IRINOTECAN AND GEMCITABINE IN PATIENTS
WITH UNRESECTABLE OR METASTATIC SOLID TUMORS Open
Protocol
PROTOCOL IDS: NU-98X3; NCI-G99-1588;
P-UPJOHN-976475157
STUDY CONTACT:
Al Bowen Benson, III, Ph: 312-695-6180
Robert H. Lurie Comprehensive Cancer Center,
Northwestern University
Chicago, Illinois
PHASE I STUDY OF IRINOTECAN AND ORAL CAPECITABINE
IN PATIENTS WITH GASTROINTESTINAL OR OTHER SOLID TUMORS Open
Protocol
PROTOCOL IDS: AECM-1199903068, NCI-V99-1541
STUDY CONTACT:
Sridhar Mani, Chair Ph: 718-904-2488
Albert Einstein Comprehensive Cancer Center
New York, New York
PHASE I STUDY OF LMB-9 IMMUNOTOXIN IN PATIENTS WITH
ADVANCED COLON, BREAST, NON-SMALL CELL LUNG, BLADDER, PANCREAS,
OR OVARIAN CANCER Open
Protocol
PROTOCOL IDS: MSGCC-9981; NCI-511;
MSGCC-IRB-0200123
STUDY CONTACT:
Petr F. Hausner, Ph: 410-328-2565
Marlene & Stewart Greenebaum Cancer Center,
University of Maryland
Baltimore, Maryland
PHASE I STUDY OF LMB-9 IMMUNOTOXIN IN PATIENTS WITH
ADVANCED SOLID TUMORS THAT EXPRESS LEWIS Y ANTIGEN Open
Protocol
PROTOCOL IDS: NCI-98-C-0078A; NCI-T98-0005;
NCI-MB-400
STUDY CONTACT:
Robert Kreitman, Ph: 301-496-6947
Medicine Branch
Bethesda, Maryland
PHASE I STUDY OF MUTANT MGMT GENE TRANSFER INTO HUMAN
HEMATOPOIETIC PROGENITORS TO PROTECT HEMATOPOIESIS DURING O6-BENZYGUANINE
AND CARMUSTINE THERAPY OF ADVANCED SOLID TUMORS AND NON-HODGKIN’S
LYMPHOMA Open
Protocol
PROTOCOL IDS: CWRU-2Y97; NCI-T97-0060
STUDY CONTACT:
Stanton L. Gerson, Chair, Ph: 216-368-1176
Ireland Cancer Center
Cleveland, Ohio
PHASE I STUDY OF PERILLYL ALCOHOL IN WOMEN AT RISK
FOR RECURRENT BREAST CANCER Open
Protocol
PROTOCOL IDS: CCF-IRB-3574, NCI-P01-0189,
CCF-N01-CN-55131
STUDY CONTACT:
G. Thomas Budd, Chair Ph: 216-444-6480
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
PHASE I STUDY OF PHOTODYNAMIC THERAPY WITH SILICON
POTHALOCYANINE 4 IN PATIENTS WITH CUTANEOUS MALIGNANCIES Open
Protocol
PROTOCOL IDS: CWRU-1Y97; NCI-T99-0007
STUDY CONTACT:
Scot C. Remick, Chair Ph: 216-844-1196
Ireland Cancer Center
Cleveland, Ohio
PHASE I STUDY OF THE ETANIDAZOLE DERIVATIVE EF5 FOR
THE DETECTION OF HYPOXIA IN PATIENTS WITH BREAST, HEAD AND NECK,
PROSTATE, OR CERVICAL CARCINOMA OR HIGH GRADE SOFT TISSUE SARCOMAS
Open
Protocol
PROTOCOL IDS: CAN-OCI-T98-0048;
NCI-T98-0048
STUDY CONTACT:
Anthony Fyles, Ph: 416-946-2123
Princess Margaret Hospital
Toronto, Ontario, Canada
PHASE I PILOT STUDY OF HER2/NEU INTRACELLULAR DOMAIN
PROTEIN PULSED AUTOLOGOUS DENDRITIC CELLS IN PATIENTS WITH HER2/NEU
EXPRESSING ADVANCED MALIGNANCIES SHOWING NO EVIDENCE OF DISEASE
AFTER STANDARD TREATMENT Open
Protocol
PROTOCOL IDS: DUMC-1309-00-7R1;
NCI-G00-1800; DUMC-1528-99-9
STUDY CONTACT:
Michael A. Morse, Ph: 919-681-3480
Duke Comprehensive Cancer Center
Durham, North Carolina
PHASE I PILOT STUDY OF NY-ESO-1 PEPTIDE VACCINE AND
SARGRAMOSTIM (GM-CSF) IN PATIENTS WITH NY-ESO-1 OR LAGE EXPRESSING
CANCER Open
protocol
PROTOCOL IDS: CPMC-IRB-13578, NCI-G01-2035,
LUD-WIG-LUD00-024
STUDY CONTACT:
Kyriakos P. Papadopoulos,
Ph: 212-305-8615
Herbert Irving Comprehensive Cancer Center
New York, New York, U.S.A.
PHASE I STUDY OF 17-N-ALLYLAMINO-17-DEMETHOXY GELDANAMYCIN
(17-AAG) IN PATIENTS WITH ADVANCED SOLID TUMORS OR REFRACTORY HEMATOLOGIC
MALIGNANCIES Open
Protocol
PROTOCOL IDS: MSKCC-99037, NCI-T99-0035
STUDY CONTACT:
Howard I. Scher, Chair Ph: 212-639-7585
Memorial Sloan-Kettering Cancer Center
New York, New York
PHASE I STUDY OF CARBOXYAMIDOTRIAZOLE PLUS PACLITAXEL
IN PATIENTS WITH ADVANCED SOLID TUMORS OR REFRACTORY LYMPHOMAS Open
Protocol
PROTOCOL IDS: NCI-95-C-0015F; NCI-T94-0006N;
NCI-CPB-334
STUDY CONTACT:
Muhrukh Hussain, Chair, Ph: 301-435-0591
Center for Cancer Research
Washington, DC
PHASE I RANDOMIZED STUDY OF MAGE-12 PEPTIDE VACCINE
IN PATIENTS WITH REFRACTORY METASTATIC CANCER EXPRESSING MAGE-12
ANTIGEN
Open Protocol
PROTOCOL IDS: NCI-00-C-0182; NCI-1034
STUDY CONTACT:
Francesco M. Marincola, Ph: 301-496-0997
Surgery Branch
Bethesda, Maryland
PHASE III RANDOMIZED STUDY OF DOCETAXEL VERSUS PACLI-TAXEL
IN WOMEN WITH METASTATIC OR LOCALLY ADVANCED, INOPERABLE ADENOCARCINOMA
OF THE BREAST Open
Protocol
PROTOCOL IDS: AVENTIS-56976-TAX-311;
NCI-V95-0680; RP-56976-TAX-311
STUDY CONTACT:
Peter Marcus Ravdin, Chair Ph: 210-567-4777
Aventis Pharmaceuticals, Inc.
PHASE II/III RANDOMIZED STUDY OF FIRST-LINE HORMONAL
THERAPY WITH EXEMESTANE VERSUS TAMOXIFEN IN POST-MENOPAUSAL WOMEN
WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER Open
Protocol
PROTOCOL IDS: EORTC-10951, PHARMACIA-EORTC-10951
STUDY CONTACT:
Robert Paridaens, Chair, Ph: 32-16-346902
EORTC Breast Cancer Group
PHASE III RANDOMIZED STUDY OF MITOXANTRONE WITH OR
WITHOUT DOCETAXEL AS FIRST-LINE CHEMOTHERAPY FOR WOMEN WITH POOR
RISK METASTATIC BREAST CANCER Open
Protocol
PROTOCOL IDS: GER-AIO-01/92; EU-93011
STUDY CONTACT:
Else G. Heidemann, Chair Ph: 0711-991-3501
Arbeitsgemeinschaft fur Internistische Onkologie Diakonissen Hospital
Stuttgart, Germany
PHASE II RANDOMIZED STUDY OF TWO DIFFERENT DOSE SCHEDULES
OF DOXORUBICIN HCL LIPOSOME IN WOMEN WITH METASTATIC BREAST CANCER
Open
Protocol
PROTOCOL IDS: IDBBC-10993
STUDY CONTACT:
Robert E. Coleman, Ph: 114-226-5213
Weston Park Hospital
Sheffield, England, United Kingdom
PHASE II RANDOMIZED STUDY OF TWO DIFFERENT SCHEDULES
OF DOCETAXEL OR PACLITAXEL IN WOMEN WITH UNRESECTABLE LOCALLY ADVANCED
OR METASTATIC BREAST CANCER OPEN
PROTOCOL
PROTOCOL IDS: FRE-GERCOR-TAXMAX-SOO-;
EU-20029; GERCOR
STUDY CONTACT:
Joseph Gligorov, Chair Ph: 1-40-30-6024
PHASE II STUDY OF BMS-247550 IN WOMEN WITH TAXANE-RESISTANT
METASTATIC BREAST CANCER Open
Protocol
PROTOCOL IDS: MSKCC-01031, NCI-G01-1967,
BMS-CA163-009
STUDY CONTACT:
Clifford A. Hudis, Chair Ph: 212-639-6483
Memorial Sloan-Kettering Cancer Center
New York, New York
PHASE II STUDY OF DOCETAXEL AND CARBOPLATIN AS FIRST
LINE THERAPY IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE BREAST
Open
Protocol
PROTOCOL IDS: NCCTG-N9932
STUDY CONTACT:
Edith A. Perez, Chair, Ph: 507-284-5369
North Central Cancer Treatment Group
Rochester, Minnesota
NEW 89 PHASE II STUDY OF DOCETAXEL AND IFOSFAMIDE
AS FIRST-LINE CHEMOTHERAPY IN WOMEN WITH METASTATIC BREAST CANCER
Open
Protocol
PROTOCOL IDS: GOCS-02-BR-01, NCI-V01-1670
STUDY CONTACT:
Bernardo A. Leone, Chair
Ph: 54-299-4485247
Grupo Oncologico Cooperativo del Sur
PHASE II STUDY OF DOCETAXEL COMBINED WITH ESTRAMUSTINE
IN PATIENTS WITH METASTATIC BREAST CANCER Open Protocol
PROTOCOL IDS: CPMC-IRB-7929; NCI-V97-1325
STUDY CONTACT:
Amy D. Tliersten, Ph: 212-305-0170
Herbert Irving Comprehensive Cancer Center
New York, New York
PHASE II STUDY OF DOCETAXEL IN ELDERLY WOMEN WITH
METASTATIC BREAST CANCER Open
Protocol
PROTOCOL ID: SWOG-S0029
STUDY CONTACT:
Silvana Martino, Chair
Ph: 310-998-3961
Southwest Oncology Group
PHASE II STUDY OF DOCETAXEL, LEUCOVORIN CALCIUM,
AND FLUOROURACIL AS SECOND OR THIRD-LINE CHEMOTHERAPY IN WOMEN WITH
LOCALLY UNRESECTABLE OR METASTATIC BREAST CANCER Open
Protocol
PROTOCOL ID: CCCWFU-74896; NCI-3137
STUDY CONTACT:
Gretchen Kimmick, Chair Ph: 336-716-0327
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina
PHASE II STUDY OF DOXORUBICIN HCL LIPOSOME AND GEMCITABINE
IN WOMEN WITH METASTATIC BREAST CANCER Open
Protocol
PROTOCOL IDS: PHARMATECH-P01-00002008,
ALZA-PHARMATECH-P01-000020008, PHARMATECH-20002183
STUDY CONTACT:
Jane Del Carlo, Chair
Ph: 720-917-7453
Pharmatech Oncology
PHASE II STUDY OF DOXORUBICIN HCL LIPOSOME AND GEMCITABINE
IN WOMEN WITH METASTATIC BREAST CANCER Open Protocol
PROTOCOL IDS: PHARMATECH-P01-00002008,
ALZA-PHARMATECH-P01-000020008, PHARMATECH-20002183
STUDY CONTACT:
Jane Del Carlo, Chair
Ph: 720-917-7453
Pharmatech Oncology
PHASE II STUDY OF DOXORUBICIN-MONOCLONAL ANTIBODY
BR96 IMMUNOCONJUGATE (SGN-15) AND DOCETAXEL IN WOMEN WITH METASTATIC
OR RECURRENT BREAST CANCER Open
Protocol
PROTOCOL IDS: SGEN-UAB-9912, UAB-9912
STUDY CONTACT:
Lisle M. Nabell, Ph: 205-934-3061
University of Alabama at Birmingham
Comprehensive Cancer Center
Birmingham, Alabama, U.S.A
PHASE II STUDY OF ETOPOSIDE, IFOSFAMIDE, MESNA, AND
CIS-PLATIN IN PATIENTS WITH METASTATIC BREAST CANCER Open
Protocol
PROTOCOL IDS: CWRU-4196; NCI-G00-1854;
BMS-CRWU-4196
STUDY CONTACT:
Paula Silverman, Ph: 216-844-8510
Ireland Cancer Center
Cleveland, Ohio
PHASE II STUDY OF FULVESTRANT (ICI 182780) IN WOMEN
WITH METASTATIC BREAST CANCER WHO HAVE FAILED AROMATASE INHIBITOR
THERAPY Open
Protocol
PROTOCOL IDS: NCCTG-N0032
STUDY CONTACT:
James N. Ingle, Chair Ph: 507-284-8432
North Central Cancer Treatment Group
PHASE II STUDY OF GEMCITABINE AND DOXORUBICIN HCL
LIPOSOME IN WOMEN WITH METASTATIC BREAST CANCER Open Protocol
PROTOCOL IDS: MDA-DM-97127; NCI-1650
STUDY CONTACT:Edgardo Rivera, Ph:
713-792-2817
University of Texas - MD Anderson Cancer Center
Houston, Texas
PHASE I/II STUDY OF DOCETAXEL AND FLAVOPIRIDOL IN
PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC
ADENOCARCINOMA OF THE BREAST Open
Protocol
PROTOCOL IDS: NCI-00-C-0212; NCI-952
STUDY CONTACT:
Sandra M. Swain, Ph: 301-496-4916
Medicine Branch
Bethesda, Maryland
PHASE II PILOT STUDY OF HIGH DOSE DOXORUBICIN, CYCLOPHOSPHAMIDE,
PACLITAXEL, AND AMIFOSTINE FOLLOWED BY PERIPHERAL STEM CELL RESCUE
IN PATIENTS WITH HIGH RISK STAGE II/III AND RESPONSIVE STAGE IV
ADVANCED BREAST CANCER Open
Protocol
PROTOCOL IDS: CHNMC-IRB-99002; NCI-G99-1527;
ALZA-CHNMC-IRB-99002
STUDY CONTACT:
George Somlo, Ph: 626-359-8111
Beckman Research Institute, City of Hope
Los Angeles, California
PHASE II PILOT STUDY OF BEVACIZUMAB, DOCETAXEL, DOXORUBICIN,
AND FILGRASTIM (G-CSF) IN PATIENTS WITH PREVIOUSLY UNTREATED STAGE
IIIB OR IV INFLAMMATORY
BREAST CANCER Open
Protocol
PROTOCOL IDS: NCI-01-C-0173, NCI-2772
STUDY CONTACTS:
Sandra M. Swain, Ph: 301-496-4916
Medicine Branch
Bethesda, Maryland, U.S.A.
Back | Top of Page
|
